Table 2

Incidence rate of VTE, DVT and PE per 100 patient-years by treatments, demographics and baseline characteristics in patients with rheumatoid arthritis

Inpatient VTEInpatient DVTInpatient PE
NCases/PYIR (95% CI)Cases/PYIR (95% CI)Cases/PYIR (95% CI)
All148 2281295/164 476.80.79 (0.75 to 0.83)936/164 742.20.57 (0.53 to 0.61)596/165 047.50.36 (0.33 to 0.39)
Treatment
b/tsDMARD switchers17 726229/26 7150.86 (0.75 to 0.98)164/26 762.90.61 (0.52 to 0.71)115/26 849.20.43 (0.35 to 0.51)
First b/tsDMARD users37 993364/54 138.10.67 (0.61 to 0.75)263/54 215.90.49 (0.43 to 0.55)165/54 297.20.30 (0.26 to 0.35)
csDMARDs92 509702/83 623.80.84 (0.78 to 0.90)509/83 763.50.61 (0.56 to 0.66)316/83 9010.38 (0.34 to 0.42)
Demographics
Sex
 Female112 451919/123 499.60.74 (0.70 to 0.79)668/123 671.80.54 (0.50 to 0.58)423/123 916.90.34 (0.31 to 0.38)
 Male35 777376/40 977.20.92 (0.83 to 1.02)268/41 070.40.65 (0.58 to 0.74)173/41 130.60.42 (0.36 to 0.49)
Age (years)
 18–4425 78394/25 570.50.37 (0.30 to 0.45)76/25 585.60.30 (0.23 to 0.37)42/25 613.70.16 (0.12 to 0.22)
 45–6472 484486/84 279.30.58 (0.53 to 0.63)337/84 3980.40 (0.36 to 0.44)240/84 506.10.28 (0.25 to 0.32)
 65–7429 907389/33 355.21.17 (1.05 to 1.29)274/33 442.20.82 (0.73 to 0.92)178/33 541.40.53 (0.46 to 0.61)
 75+20 054326/21 271.81.53 (1.37 to 1.71)249/21 316.51.17 (1.03 to 1.32)136/21 386.30.64 (0.53 to 0.75)
Race
 White100 091955/117 943.60.81 (0.76 to 0.86)694/118 146.70.59 (0.54 to 0.63)443/118 360.60.37 (0.34 to 0.41)
 Black13 792135/13 991.20.96 (0.81 to 1.14)93/14 016.40.66 (0.54 to 0.81)60/14 078.70.43 (0.33 to 0.55)
 Hispanic17 27199/16 448.40.60 (0.49 to 0.73)75/16 464.30.46 (0.36 to 0.57)38/16 478.30.23 (0.16 to 0.32)
 Asian363020/3883.40.52 (0.31 to 0.80)10/3887.40.26 (0.12 to 0.47)12/3891.40.31 (0.16 to 0.54)
 Unknown646486/12 210.30.70 (0.56 to 0.87)64/12 227.30.52 (0.40 to 0.67)43/12 238.60.35 (0.25 to 0.47)
Medical history
VTE
 Yes4876284/4342.66.54 (5.80 to 7.35)207/4414.94.69 (4.07 to 5.37)113/4472.12.53 (2.08 to 3.04)
 No143 3521011/160 134.30.63 (0.59 to 0.67)729/160 327.30.45 (0.42 to 0.49)483/160 575.40.30 (0.27 to 0.33)
Medication use history
Anticoagulants
 Yes11 660345/11 466.13.01 (2.7 to 3.34)247/11 562.32.14 (1.88 to 2.42)143/11 6161.23 (1.04 to 1.45)
 No136 568950/153 010.80.62 (0.58 to 0.66)689/153 179.90.45 (0.42 to 0.48)453/153 431.50.30 (0.27 to 0.32)
VTE and anticoagulants
 Yes2945224/2571.98.71 (7.61 to 9.93)161/2639.56.10 (5.19 to 7.12)90/2673.93.37 (2.71 to 4.14)
 No145 2831071/161 9050.66 (0.62 to 0.70)775/162 102.70.48 (0.45 to 0.51)506/162 373.60.31 (0.29 to 0.34)
  • b/tsDMARD, biologic or targeted synthetic disease-modifying antirheumatic drug; csDMARD, conventional synthetic DMARD; DVT, deep vein thrombosis;IR, incidence rate; PE, pulmonary embolism; VTE, venous thromboembolism.